Italy · Delayed Price · Currency is EUR Pharmanutra Statistics
Total Valuation
Pharmanutra has a market cap or net worth of EUR 458.55 million. The enterprise value is 451.85 million.
| Market Cap | 458.55M |
| Enterprise Value | 451.85M |
Important Dates
The next estimated earnings date is Monday, September 8, 2025.
| Earnings Date | Sep 8, 2025 |
| Ex-Dividend Date | May 5, 2025 |
Share Statistics
Pharmanutra has 9.60 million shares outstanding. The number of shares has decreased by -0.83% in one year.
| Current Share Class | 9.60M |
| Shares Outstanding | 9.60M |
| Shares Change (YoY) | -0.83% |
| Shares Change (QoQ) | +1.53% |
| Owned by Insiders (%) | 10.77% |
| Owned by Institutions (%) | 13.99% |
| Float | 4.25M |
Valuation Ratios
The trailing PE ratio is 27.95 and the forward PE ratio is 21.00.
| PE Ratio | 27.95 |
| Forward PE | 21.00 |
| PS Ratio | 3.86 |
| PB Ratio | 7.11 |
| P/TBV Ratio | 11.21 |
| P/FCF Ratio | 22.16 |
| P/OCF Ratio | 18.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.73, with an EV/FCF ratio of 21.83.
| EV / Earnings | 27.53 |
| EV / Sales | 3.80 |
| EV / EBITDA | 14.73 |
| EV / EBIT | 16.52 |
| EV / FCF | 21.83 |
Financial Position
The company has a current ratio of 2.29, with a Debt / Equity ratio of 0.37.
| Current Ratio | 2.29 |
| Quick Ratio | 2.02 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 0.78 |
| Debt / FCF | 1.16 |
| Interest Coverage | 30.13 |
Financial Efficiency
Return on equity (ROE) is 26.90% and return on invested capital (ROIC) is 19.66%.
| Return on Equity (ROE) | 26.90% |
| Return on Assets (ROA) | 14.32% |
| Return on Invested Capital (ROIC) | 19.66% |
| Return on Capital Employed (ROCE) | 29.72% |
| Revenue Per Employee | 1.01M |
| Profits Per Employee | 139,102 |
| Employee Count | 118 |
| Asset Turnover | 1.00 |
| Inventory Turnover | 6.83 |
Taxes
In the past 12 months, Pharmanutra has paid 10.85 million in taxes.
| Income Tax | 10.85M |
| Effective Tax Rate | 39.91% |
Stock Price Statistics
The stock price has decreased by -12.04% in the last 52 weeks. The beta is 0.30, so Pharmanutra's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -12.04% |
| 50-Day Moving Average | 46.91 |
| 200-Day Moving Average | 50.85 |
| Relative Strength Index (RSI) | 52.88 |
| Average Volume (20 Days) | 4,393 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmanutra had revenue of EUR 118.93 million and earned 16.41 million in profits. Earnings per share was 1.71.
| Revenue | 118.93M |
| Gross Profit | 62.02M |
| Operating Income | 27.36M |
| Pretax Income | 27.19M |
| Net Income | 16.41M |
| EBITDA | 30.23M |
| EBIT | 27.36M |
| Earnings Per Share (EPS) | 1.71 |
Balance Sheet
The company has 30.76 million in cash and 24.06 million in debt, giving a net cash position of 6.71 million or 0.70 per share.
| Cash & Cash Equivalents | 30.76M |
| Total Debt | 24.06M |
| Net Cash | 6.71M |
| Net Cash Per Share | 0.70 |
| Equity (Book Value) | 64.47M |
| Book Value Per Share | 6.62 |
| Working Capital | 40.34M |
Cash Flow
In the last 12 months, operating cash flow was 24.86 million and capital expenditures -4.16 million, giving a free cash flow of 20.69 million.
| Operating Cash Flow | 24.86M |
| Capital Expenditures | -4.16M |
| Free Cash Flow | 20.69M |
| FCF Per Share | 2.15 |
Margins
Gross margin is 52.15%, with operating and profit margins of 23.00% and 13.80%.
| Gross Margin | 52.15% |
| Operating Margin | 23.00% |
| Pretax Margin | 22.86% |
| Profit Margin | 13.80% |
| EBITDA Margin | 25.42% |
| EBIT Margin | 23.00% |
| FCF Margin | 17.40% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 2.09%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 2.09% |
| Dividend Growth (YoY) | 17.65% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 49.79% |
| Buyback Yield | 0.83% |
| Shareholder Yield | 2.91% |
| Earnings Yield | 3.58% |
| FCF Yield | 4.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 8 |